C-REACTIVE PROTEIN (CRP) AS A PROGNOSTIC BIOMARKER IN ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH IMMUNE CHECKPOINT

33 Figure 1 WGS of plasma increases sensitivity in low- burden disease Likelihood of ctDNA SNV detection is a function of tumor Because the limited genomic equivalents targeted sequencing, detection limited by the relatively small number of in clinical panel. In contrast, WGS at modest depth (35x) low tumor integrating of the Abstract 33 Figure 2 Phoenix learns key covariates for melanoma ctDNAPhoenix was trained on tumor-confirmed in plasma from patients with high burden and cfDNA from age-matched patients without known We and predictions on from a held out validation Phoenix ctDNA predictions correctly reflect important melanoma SNV attributes including UV- signature (C>T trinucleotide context, low DNase accessibility late replication timing Abstract 33 Figure 3 Phoenix sensitively tracks response to nivolumabPlasmasamples were collected to monitor treatment response to nivolumab. Treatment monitoring by computed tomography (CT) shows response to therapy but residual disease after 3 months of therapy (a). Phoenix quantifies tumor response, matching radiographic changes, in higher temporal resolution than what is feasible with imaging (b). IchorCNA sensitivity captures initial treatment response dynamics but does not detect residual disease after 3 months of treatment (c). Log score is calculated from a single plasma sample for each timepoint compared to a panel of control samples (n = 37). was measured as detection rate among post-filter candidate SNVs and compared to a 97% specificity boundary among a panel of healthy controls. Phoenix detects a response to checkpoint blockade, measured as a decrease in ctDNA detection rate, as early as 3 weeks as shown in 3 patients (MSK-38, MSK-40, MSK 42).